Pharming Group N.V. | Mutual Funds
Mutual Funds that own Pharming Group N.V.
Fidelity Select Biotechnology Portfolio
19,512,456
3.37%
0
0.31%
07/31/2018
Polar Capital Funds Plc - Biotechnology Fund
7,500,000
1.3%
-2,500,000
2.24%
07/31/2018
AXA Framlington Biotech Fund
6,118,478
1.06%
-2,829,105
1.27%
02/28/2018
Fidelity Advisor Biotechnology Fund
6,009,781
1.04%
0
0.31%
07/31/2018
iShares MSCI EAFE Small Cap ETF
2,809,249
0.49%
0
0.04%
09/06/2018
iShares Core MSCI EAFE ETF
2,357,606
0.41%
0
0.01%
09/06/2018
iShares MSCI EMU Small Cap UCITS ETF
1,146,588
0.2%
0
0.14%
09/06/2018
Russell Invt. Co. Plc - Continental European Equity Fund (The)
496,852
0.09%
496,852
0.12%
03/31/2018
CS Director Growth, FI
452,288
0.08%
452,288
3.09%
12/31/2017
db x-trackers MSCI Europe Small Cap TRN Index ETF
417,917
0.07%
0
0.06%
09/06/2018
| Address |
Darwinweg 24
Leiden Zuid-Holland 2333 CR
Netherlands
|
|
Employees
|
- |
| Website |
http://www.pharming.com |
| Updated |
07/08/2019 |
| Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. |
